Dengue-2 Cosmopolitan genotype detection and emergence in South America

We report the first confirmed case of DENV-2 Cosmopolitan genotype isolated from a male patient from Aparecida de Goiania, Goías state, Midwest Brazil. Using nanopore sequencing, and phylogenetic analyses our findings provide the first preliminary insight regarding the introduction of this emerging genotype in Brazil and South America. Article Summary Line Molecular detection of Dengue virus type 2 Cosmopolitan genotype in South America ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was support in part through National Institutes of Health USA grant U01 AI151698 for the United World Antiviral Research Network (UWARN), the National Council for Scientific Development- CNPq (421598/2018-2) and by the Brazilian Ministry of Health (SCON2021-00180). MG and LCJA are supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). Peru DENV 2 sequences were obtained in the frame of the PAHO VIGENDA project (VIgilancia GEnomica de Dengue en las Americas as per is acronym in Spanish). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This project was reviewed and approved by the Pan American Health Organization Ethics Review Committee (PAHOERC) (Ref. No. PAHO 2016-08-0029) and by the Federal University of Minas Gerais (CEP CAAE: 32912820.6.1001.5149). The availability of these samples for research purposes during outbreaks of national concern is allowed to the terms of the 510 2016 Resolution of the National Ethical Committee for Research Brazilian Ministry of Health (CONEP Comissao Nacional de Etica em Pesquisa, Ministerio da Saude), that authorize, without the necessity of an informed consent, the use of clinical samples collected in the Brazilian Central Public Health Laboratories to accelerate knowledge building and contribute to surveillance and outbreak response. The sample processed in this study was obtained anonymously from material exceeding the routine diagnosis of arboviruses in Brazilian public health laboratories that belong to the public network within BrMoH. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The newly sequence data obtained in this study was deposited in GenBank, accession number [OM744143][1]. [1]: /lookup/external-ref?link_type=GEN&access_num=OM744143&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F05%2F2022.03.29.22273028.atom